Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395054 | 0.87 | CA1 (0.43) | GAASMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL394504 | 0.86 | SCN1A (0.47) | KMT2AMEN1PKMKDM4ESMN1; SMN2 | |
| SCHEMBL395297 | 0.84 | TDP1 (0.36) | L3MBTL1 | |
| SCHEMBL393666 | 0.83 | KMT2A (0.43) | KMT2AMEN1KDM4EGAASMN1; SMN2 | |
| SCHEMBL394359 | 0.79 | HRH3 (0.43) | KMT2AKDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL394161 | 0.79 | RAB9A (0.43) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL390172 | 0.78 | ADRB2 (0.43) | KMT2AMEN1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL393282 | 0.78 | ADRB2 (0.43) | KMT2AKDM4ESMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL395449 | 0.78 | NPSR1 (0.43) | SMN1; SMN2MAPTALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL392988 | 0.77 | KDM4E (0.46) | KMT2AMEN1KDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919879-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | claimed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | claimed |
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | Q6ZSR9, GMPS, RPS10 | KMT2A 2161/4885MEN1 1471/4885PKM 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.